• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome.腹泻型肠易激综合征患者的腔内和黏膜相关肠道微生物组的分子分析。
Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G799-807. doi: 10.1152/ajpgi.00154.2011. Epub 2011 Jul 7.
2
Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.腹泻型肠易激综合征患者的粪便和黏膜相关肠道微生物群。
Dig Dis Sci. 2018 Jul;63(7):1890-1899. doi: 10.1007/s10620-018-5086-4. Epub 2018 May 17.
3
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.腹泻型肠易激综合征患者肠道微生物群落组成和多样性的改变。
Neurogastroenterol Motil. 2012 Jun;24(6):521-30, e248. doi: 10.1111/j.1365-2982.2012.01891.x. Epub 2012 Feb 20.
4
A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome.肠易激综合征患者粪便和黏膜细菌群落的分子分析。
Dig Dis Sci. 2010 Feb;55(2):392-7. doi: 10.1007/s10620-009-0934-x. Epub 2009 Aug 20.
5
Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.腹泻型肠易激综合征患者粪便初级胆汁酸增加和肠道菌群失调。
Neurogastroenterol Motil. 2012 Jun;24(6):513-20, e246-7. doi: 10.1111/j.1365-2982.2012.01893.x. Epub 2012 Feb 22.
6
Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression.腹泻型肠易激综合征和抑郁症患者粪便微生物群特征相似。
Clin Gastroenterol Hepatol. 2016 Nov;14(11):1602-1611.e5. doi: 10.1016/j.cgh.2016.05.033. Epub 2016 Jun 4.
7
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome.腹泻型肠易激综合征中小肠细菌过度生长相关的十二指肠和直肠黏膜微生物群。
J Gastroenterol Hepatol. 2020 May;35(5):795-805. doi: 10.1111/jgh.14910. Epub 2019 Nov 5.
8
Gut microbial signatures of patients with diarrhea-predominant irritable bowel syndrome and their healthy relatives.腹泻型肠易激综合征患者及其健康亲属的肠道微生物特征。
J Appl Microbiol. 2024 Jun 3;135(6). doi: 10.1093/jambio/lxae118.
9
Involvement of mucosal flora and enterochromaffin cells of the caecum and descending colon in diarrhoea-predominant irritable bowel syndrome.回盲部和降结肠的黏膜菌群和肠嗜铬细胞参与腹泻为主的肠易激综合征。
BMC Microbiol. 2021 Nov 13;21(1):316. doi: 10.1186/s12866-021-02380-2.
10
Involvement of shared mucosal-associated microbiota in the duodenum and rectum in diarrhea-predominant irritable bowel syndrome.共享黏膜相关微生物群在腹泻为主的肠易激综合征的十二指肠和直肠中的作用。
J Gastroenterol Hepatol. 2018 Jun;33(6):1220-1226. doi: 10.1111/jgh.14059. Epub 2018 Feb 26.

引用本文的文献

1
The relationship between gut microbiome and human diseases: mechanisms, predisposing factors and potential intervention.肠道微生物群与人类疾病之间的关系:机制、易感因素和潜在干预措施。
Front Cell Infect Microbiol. 2025 May 6;15:1516010. doi: 10.3389/fcimb.2025.1516010. eCollection 2025.
2
Host Transcriptome and Microbial Variation in Relation to Visceral Hyperalgesia.与内脏痛觉过敏相关的宿主转录组和微生物变异
Nutrients. 2025 Mar 6;17(5):921. doi: 10.3390/nu17050921.
3
Gut microbial dysbiosis associated to diarrheic irritable bowel syndrome can be efficiently simulated in the Mucosal ARtificial COLon (M-ARCOL).与腹泻型肠易激综合征相关的肠道微生物失调可以在黏膜人工结肠(M-ARCOL)中得到有效模拟。
Bioengineered. 2025 Dec;16(1):2458362. doi: 10.1080/21655979.2025.2458362. Epub 2025 Feb 4.
4
Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.探索肠易激综合征中的肠道微生物群失衡:益生菌及其代谢产物的潜在治疗作用
Nutrients. 2024 Dec 31;17(1):155. doi: 10.3390/nu17010155.
5
Comparing lactic acid bacteria biodiversity in irritable bowel syndrome and healthy gut microbiota.比较肠易激综合征与健康肠道微生物群中的乳酸菌生物多样性。
Food Sci Nutr. 2024 Sep 30;12(11):9212-9226. doi: 10.1002/fsn3.4477. eCollection 2024 Nov.
6
Probiotics and Prebiotics for the Treatment of Irritable Bowel Syndrome-A Narrative Review.用于治疗肠易激综合征的益生菌和益生元——一篇叙述性综述
J Clin Med. 2024 Oct 23;13(21):6337. doi: 10.3390/jcm13216337.
7
Novel hypothesis and therapeutic interventions for irritable bowel syndrome: interplay between metal dyshomeostasis, gastrointestinal dysfunction, and neuropsychiatric symptoms.肠易激综合征的新假说与治疗干预:金属稳态失衡、胃肠功能障碍和神经精神症状之间的相互作用
Mol Cell Biochem. 2025 May;480(5):2661-2676. doi: 10.1007/s11010-024-05153-3. Epub 2024 Nov 6.
8
Analysis of fungal diversity in the feces of .……粪便中真菌多样性的分析。(原文不完整,翻译可能存在一定局限性)
Front Vet Sci. 2024 Oct 14;11:1430518. doi: 10.3389/fvets.2024.1430518. eCollection 2024.
9
Recombinant Lactiplantibacilllus plantarum modulate gut microbial diversity and function.重组植物乳杆菌调节肠道微生物多样性和功能。
BMC Microbiol. 2024 Oct 22;24(1):423. doi: 10.1186/s12866-024-03570-4.
10
Intestinal Energy Harvest Mediates Gut Microbiota-Associated Weight Loss Following Bariatric Surgery.肠道能量获取介导减肥手术后肠道微生物群相关的体重减轻。
Obes Surg. 2024 Oct;34(10):3771-3780. doi: 10.1007/s11695-024-07467-z. Epub 2024 Aug 28.

本文引用的文献

1
Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial.益生菌发酵乳对肠易激综合征患者症状及肠道菌群的影响:一项随机、安慰剂对照试验
Scand J Gastroenterol. 2011 Jun;46(6):663-72. doi: 10.3109/00365521.2011.565066. Epub 2011 Mar 28.
2
Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study.嗜酸乳杆菌 NCFM 和两歧双歧杆菌 Bi-07 对功能性肠病患者腹胀症状的益生菌治疗:一项双盲研究。
J Clin Gastroenterol. 2011 Jul;45(6):518-25. doi: 10.1097/MCG.0b013e31820ca4d6.
3
Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.随机临床试验:双歧杆菌 MIMBb75 显著缓解肠易激综合征并提高生活质量——一项双盲、安慰剂对照研究。
Aliment Pharmacol Ther. 2011 May;33(10):1123-32. doi: 10.1111/j.1365-2036.2011.04633.x. Epub 2011 Mar 21.
4
A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.布拉氏酵母菌散剂治疗肠易激综合征的随机、双盲、安慰剂对照、多中心临床试验:对生活质量的影响。
J Clin Gastroenterol. 2011 Sep;45(8):679-83. doi: 10.1097/MCG.0b013e318204593e.
5
Rifaximin therapy for patients with irritable bowel syndrome without constipation.利福昔明治疗无便秘型肠易激综合征患者。
N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.
6
Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.腹泻型肠易激综合征患者的腔内和黏膜相关肠道微生物群。
Gut Pathog. 2010 Dec 9;2(1):19. doi: 10.1186/1757-4749-2-19.
7
Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis.肠杆菌科与肠道微生物群协同作用,引发自发性和母传结肠炎。
Cell Host Microbe. 2010 Sep 16;8(3):292-300. doi: 10.1016/j.chom.2010.08.004.
8
A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes.一项在双胞胎中进行的焦磷酸测序研究表明,胃肠道微生物谱随炎症性肠病表型而变化。
Gastroenterology. 2010 Dec;139(6):1844-1854.e1. doi: 10.1053/j.gastro.2010.08.049. Epub 2010 Oct 8.
9
Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas.黏膜黏附菌的分子特征及其与结直肠腺瘤的关系。
Gut Microbes. 2010 May-Jun;1(3):138-47. doi: 10.4161/gmic.1.3.12360. Epub 2010 May 13.
10
Assessing gut microbial diversity from feces and rectal mucosa.评估粪便和直肠黏膜中的肠道微生物多样性。
Microb Ecol. 2011 Jan;61(1):123-33. doi: 10.1007/s00248-010-9738-y. Epub 2010 Aug 24.

腹泻型肠易激综合征患者的腔内和黏膜相关肠道微生物组的分子分析。

Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome.

机构信息

Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, 27599-7080, USA.

出版信息

Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G799-807. doi: 10.1152/ajpgi.00154.2011. Epub 2011 Jul 7.

DOI:10.1152/ajpgi.00154.2011
PMID:21737778
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3220325/
Abstract

Alterations in the intestinal microbiota have been suggested as an etiological factor in the pathogenesis of irritable bowel syndrome (IBS). This study used a molecular fingerprinting technique to compare the composition and biodiversity of the microbiota within fecal and mucosal niches between patients with diarrhea-predominant IBS (D-IBS) and healthy controls. Terminal-restriction fragment (T-RF) length polymorphism (T-RFLP) fingerprinting of the bacterial 16S rRNA gene was used to perform microbial community composition analyses on fecal and mucosal samples from patients with D-IBS (n = 16) and healthy controls (n = 21). Molecular fingerprinting of the microbiota from fecal and colonic mucosal samples revealed differences in the contribution of T-RFs to the microbiota between D-IBS patients and healthy controls. Further analysis revealed a significantly lower (1.2-fold) biodiversity of microbes within fecal samples from D-IBS patients than healthy controls (P = 0.008). No difference in biodiversity in mucosal samples was detected between D-IBS patients and healthy controls. Multivariate analysis of T-RFLP profiles demonstrated distinct microbial communities between luminal and mucosal niches in all samples. Our findings of compositional differences in the luminal- and mucosal-associated microbiota between D-IBS patients and healthy controls and diminished microbial biodiversity in D-IBS fecal samples further support the hypothesis that alterations in the intestinal microbiota may have an etiological role in the pathogenesis of D-IBS and suggest that luminal and mucosal niches need to be investigated.

摘要

肠道微生物群的改变被认为是肠易激综合征(IBS)发病机制中的一个病因因素。本研究使用分子指纹技术比较了腹泻型肠易激综合征(D-IBS)患者和健康对照者粪便和黏膜龛内微生物群的组成和生物多样性。对来自 D-IBS 患者(n=16)和健康对照者(n=21)的粪便和黏膜样本的细菌 16S rRNA 基因进行末端限制性片段(T-RF)长度多态性(T-RFLP)指纹分析,以进行微生物群落组成分析。来自粪便和结肠黏膜样本的微生物群的分子指纹分析显示,D-IBS 患者和健康对照者的微生物群中 T-RF 的贡献存在差异。进一步分析显示,D-IBS 患者粪便样本中的微生物生物多样性明显较低(1.2 倍)(P=0.008)。在 D-IBS 患者和健康对照者的黏膜样本中未检测到生物多样性的差异。T-RFLP 图谱的多变量分析显示,所有样本中腔隙和黏膜龛之间的微生物群落存在明显差异。我们在 D-IBS 患者和健康对照者的腔隙和黏膜相关微生物群之间发现了组成差异,并且 D-IBS 粪便样本中的微生物生物多样性减少,这进一步支持了肠道微生物群的改变可能在 D-IBS 的发病机制中起病因作用的假说,并表明需要研究腔隙和黏膜龛。